Retatrutide… What’s All the Fuss About?

Retatrutide is generating a lot of attention because early trial data suggest even greater weight‑loss and metabolic benefits than current GLP‑1 and dual‑agonist drugs such as semaglutide and tirzepatide.
However, it is still an investigational medicine and cannot legally be prescribed in the UK outside authorised clinical trials.

1. Semaglutide, Tirzepatide and Retatrutide – How Do They Differ?

All three are once‑weekly injectable drugs that act on gut‑hormone pathways to influence appetite, insulin secretion and energy balance.

Receptor targets

DrugMain receptor targetsSemaglutideGLP‑1 receptor agonist only – weekly injectionTirzepatideDual GIP and GLP‑1 receptor agonistRetatrutideTriple agonist: GIP, GLP‑1 and glucagon (GCGR) – weekly injection

In simple terms:

• Semaglutide selectively activates GLP‑1 receptors, boosting glucose‑dependent insulin release, slowing gastric emptying and increasing satiety.

• Tirzepatide adds GIP agonism to GLP‑1, further amplifying insulin secretion and weight loss compared with GLP‑1 alone.

• Retatrutide adds glucagon‑receptor agonism on top of GIP/GLP‑1, with the aim of increasing energy expenditure, fat burning and liver‑fat reduction while still improving blood sugar control.

2. Why Retatrutide Looks Different Mechanistically

• GLP‑1 agonism (all three):
  • Increases insulin when glucose is high
  • Reduces glucagon when glucose is high
  • Slows gastric emptying
  • Acts in the brain to reduce appetite and support weight loss and glycaemic control
• GIP agonism (tirzepatide, retatrutide):
  • Appears to work with GLP‑1 to further enhance insulin secretion and satiety
  • In combination leads to greater weight loss than GLP‑1 alone in obesity and type 2 diabetes studies
• Glucagon‑receptor agonism (retatrutide only):
  • Used here to increase energy expenditure, promote lipid oxidation and reduce liver fat
  • GLP‑1/GIP effects help counterbalance any risk of high blood sugar from glucagon activation

This triple‑agonist profile is probably why retatrutide has produced very large relative weight reductions and strong metabolic improvements in early studies.

3. What Do the Trials Show So Far?

Phase 2 obesity trial (NEJM 2023)

In adults with obesity or overweight (without diabetes):

• Weekly retatrutide achieved ~16–17.5% mean weight loss at 24 weeks

• At 48 weeks on the highest doses, mean loss reached around 22–24%

• Placebo patients lost very little weight

• Side‑effects were broadly similar to current GLP‑1 / GIP–GLP‑1 drugs (mostly gastrointestinal, dose‑dependent)

Other phase 2 data and reviews

• Narrative and mechanistic reviews describe retatrutide as a promising “triple G agonist” with larger weight‑loss effects than current agents at comparable time‑points.

• Improvements have also been seen in glycaemic control and markers of non‑alcoholic steatohepatitis / metabolic steatotic liver disease.

• Comparative work suggests that multi‑receptor agonists (dual or triple) tend to deliver stronger anti‑obesity effects than GLP‑1 alone because they combine GLP‑1, GIP and glucagon pathways.

In headline terms, a once‑weekly injection has produced ~20–25% average weight loss in under a year in phase‑2 trials – approaching the range seen with some bariatric‑surgery cohorts, although in very carefully selected trial populations and with an experimental drug.

4. Regulatory Status – Can You Get Retatrutide in the UK?

• Retatrutide is an Eli Lilly investigational drug currently in phase 3 TRIUMPH trials for obesity, diabetes, sleep apnoea and related indications.

• As of early 2026 it has no marketing authorisation from the MHRA and is not approved by any major regulator for routine use.

• In the UK it cannot be prescribed or supplied for everyday clinical use; access is limited to participation in authorised clinical trials or tightly regulated research‑only settings.

By contrast, semaglutide and tirzepatide (Mounjaro) are already licensed for diabetes and, in some formulations, obesity in multiple countries (including the UK), subject to local criteria and availability.

5. Cardiovascular Outcomes – Where Do We Stand?

We also have to consider heart‑ and kidney‑outcome data.

• Semaglutide
  • Multiple cardiovascular‑outcome trials (SUSTAIN‑6, PIONEER‑6) in high‑risk type 2 diabetes show roughly 24% relative risk reduction in major adverse cardiovascular events (MACE) vs placebo.
  • The SELECT trial in people with overweight/obesity and established cardiovascular disease (without diabetes) also showed reduced MACE, strengthening its CV‑benefit profile.
• Tirzepatide (Mounjaro)
  • SURPASS‑CVOT (NEJM 2025) found tirzepatide non‑inferior to dulaglutide for MACE in adults with type 2 diabetes and atherosclerotic CVD, with numerically fewer events but no proven superiority yet.
  • Overall CV‑outcome evidence is encouraging but not as extensive as for semaglutide.
• Retatrutide
  • Phase‑2 data show improvements in weight, lipids and traditional CV risk factors.
  • There is no completed hard‑endpoint cardiovascular‑outcome trial yet; studies such as TRIUMPH‑OUTCOMES are ongoing to look at MACE and kidney outcomes.

6. Key Take‑Home Points on Retatrutide

• Retatrutide is a triple GIP/GLP‑1/glucagon agonist that has produced very impressive weight‑loss and metabolic results in early trials.

• It is not licensed for routine prescribing in the UK (or elsewhere) and is currently only available within clinical trials.

• Established drugs like semaglutide and tirzepatide already have substantial safety and cardiovascular‑outcomes data and remain the evidence‑based options for most patients at present.

• Any future use of retatrutide in routine care will depend on ongoing phase‑3 and outcome trials, regulatory decisions, and updated clinical guidelines.

‍